These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12388820)

  • 61. Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection.
    Karupiah G; Blanden RV; Ramshaw IA
    J Exp Med; 1990 Nov; 172(5):1495-503. PubMed ID: 2121889
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.
    Chahroudi A; Garber DA; Reeves P; Liu L; Kalman D; Feinberg MB
    J Virol; 2006 Sep; 80(17):8469-81. PubMed ID: 16912297
    [TBL] [Abstract][Full Text] [Related]  

  • 63. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2.
    van Den Broek M; Bachmann MF; Köhler G; Barner M; Escher R; Zinkernagel R; Kopf M
    J Immunol; 2000 Jan; 164(1):371-8. PubMed ID: 10605032
    [TBL] [Abstract][Full Text] [Related]  

  • 64. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites.
    Karupiah G; Harris N
    J Exp Med; 1995 Jun; 181(6):2171-9. PubMed ID: 7539042
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
    Harrington LE; Most Rv Rv; Whitton JL; Ahmed R
    J Virol; 2002 Apr; 76(7):3329-37. PubMed ID: 11884558
    [TBL] [Abstract][Full Text] [Related]  

  • 67. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection.
    Tanaka-Kataoka M; Kunikata T; Takayama S; Iwaki K; Ohashi K; Ikeda M; Kurimoto M
    Cytokine; 1999 Aug; 11(8):593-9. PubMed ID: 10433806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs.
    Büttner M; Czerny CP; Lehner KH; Wertz K
    Vet Immunol Immunopathol; 1995 Jun; 46(3-4):237-50. PubMed ID: 7502485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A recombinant vaccinia virus encoding inducible nitric oxide synthase is attenuated in vivo.
    Rolph MS; Cowden WB; Medveczky CJ; Ramshaw IA
    J Virol; 1996 Nov; 70(11):7678-85. PubMed ID: 8892888
    [TBL] [Abstract][Full Text] [Related]  

  • 70. IFN-gamma, TNF, and IL-6 production by vaccinia virus immune spleen cells. An in vitro study.
    Carpenter EA; Ruby J; Ramshaw IA
    J Immunol; 1994 Mar; 152(6):2652-9. PubMed ID: 8144873
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Nucleotide sequence of XhoI O fragment of ectromelia virus DNA reveals significant differences from vaccinia virus.
    Senkevich TG; Muravnik GL; Pozdnyakov SG; Chizhikov VE; Ryazankina OI; Shchelkunov SN; Koonin EV; Chernos VI
    Virus Res; 1993 Oct; 30(1):73-88. PubMed ID: 8266721
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma.
    Chen B; Timiryasova TM; Haghighat P; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
    J Immunother; 2001; 24(1):46-57. PubMed ID: 11211148
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Vaccinia virus complement control protein modulates adaptive immune responses during infection.
    Girgis NM; Dehaven BC; Xiao Y; Alexander E; Viner KM; Isaacs SN
    J Virol; 2011 Mar; 85(6):2547-56. PubMed ID: 21191012
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release.
    Meiser A; Boulanger D; Sutter G; Krijnse Locker J
    J Gen Virol; 2003 Jun; 84(Pt 6):1383-1392. PubMed ID: 12771405
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine.
    Prichard MN; Kern ER; Quenelle DC; Keith KA; Moyer RW; Turner PC
    Virol J; 2008 Mar; 5():39. PubMed ID: 18321387
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A recombinant vaccinia virus encoding the interferon-inducible T-cell alpha chemoattractant is attenuated in vivo.
    Hamilton NH; Mahalingam S; Banyer JL; Ramshaw IA; Thomson SA
    Scand J Immunol; 2004 Mar; 59(3):246-54. PubMed ID: 15030574
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vaccinia virus F1L protein promotes virulence by inhibiting inflammasome activation.
    Gerlic M; Faustin B; Postigo A; Yu EC; Proell M; Gombosuren N; Krajewska M; Flynn R; Croft M; Way M; Satterthwait A; Liddington RC; Salek-Ardakani S; Matsuzawa S; Reed JC
    Proc Natl Acad Sci U S A; 2013 May; 110(19):7808-13. PubMed ID: 23603272
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
    Gherardi MM; Ramírez JC; Esteban M
    J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses.
    Holgado MP; Falivene J; Maeto C; Amigo M; Pascutti MF; Vecchione MB; Bruttomesso A; Calamante G; Del Médico-Zajac MP; Gherardi MM
    Viruses; 2016 May; 8(5):. PubMed ID: 27223301
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.
    Zhang WH; Wilcock D; Smith GL
    J Virol; 2000 Dec; 74(24):11654-62. PubMed ID: 11090164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.